APA (7th ed.) Citation

O, E., AG, Y., JH, S., CJ, T., JS, C., DJ, L., . . . SK, B. (2025). Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. Journal of the American Academy of Dermatology, 92(3), 634. https://doi.org/10.1016/j.jaad.2024.10.095

Chicago Style (17th ed.) Citation

O, Elghawy, et al. "Retrospective Cohort Study of Novel Oral Agents Lenalidomide and Duvelisib for Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome." Journal of the American Academy of Dermatology 92, no. 3 (2025): 634. https://doi.org/10.1016/j.jaad.2024.10.095.

MLA (9th ed.) Citation

O, Elghawy, et al. "Retrospective Cohort Study of Novel Oral Agents Lenalidomide and Duvelisib for Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome." Journal of the American Academy of Dermatology, vol. 92, no. 3, 2025, p. 634, https://doi.org/10.1016/j.jaad.2024.10.095.